Becton, Dickinson and Company (NYSE:BDX) is a medical device company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products.

Becton, Dickinson acquired CareFusion, which enabled the firm to offer medication management and patient safety solutions, as well as respiratory devices. The C.R. Bard acquisition led to the ...

Shares of Becton Dickinson & Co. BDX shed 2.46% to $171.02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.10% to ...

Becton, Dickinson and Company and its subsidiary, C.R. Bard, face more than 400 lawsuits related to their use of a carcinogenic gas to sterilize medical equipment in Covington.

In addition, Becton, Dickinson, and Company (NYSE:BDX) is planning a $2.5 billion investment in the US as it looks to enhance its manufacturing capacity in response to the trade tariffs.

Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.

Becton, Dickinson and Company and its predecessor, C.R. Bard, were hit Friday with a $20 million verdict in a landmark toxic exposure trial tied to the companies' facility in Covington, Georgia.

Becton Dickinson & Co.’s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its ...

But making Becton, Dickinson & Co an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of BDX entered into oversold territory, changing hands as low ...

Photo: mehdi fedouach/Agence France-Presse/Getty Images Becton Dickinson BDX 0.92% and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology.

16:31 EST Becton Dickinson (BDX) to separate biosciences, diagnostic solutions business Maximize Your Portfolio with Data Driven Insights: Leverage the power of TipRanks' Smart Score, a data ...

Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to ...